RecruitingPhase 1NCT06863233

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

5 participants

Start Date

Mar 3, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancer

Summary

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a specialized imaging scan to track immune cells called CD8+ T cells inside the body during treatment, to better understand how an engineered immune cell therapy (TIL therapy) works in people with advanced non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic non-small cell lung cancer (confirmed by biopsy) - You are already enrolled in the TIL cell therapy protocol (OBX115-23-01) but have not yet received the treatment - You agree to use effective contraception if you could become pregnant **You may NOT be eligible if...** - You have not been enrolled in the OBX115-23-01 TIL therapy study - You have already received the TIL cell therapy treatment - You do not have metastatic NSCLC Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZirconium Zr 89 crefmirlimab berdoxam

Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.

DIAGNOSTIC_TESTPET/CT Scan

Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).